Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications-Reference-Cited by-同舟云学术

Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications

Published:2019-07-25 Issue:21 Volume:25 Page:6339-6345
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Rahman Rifaquat,Fell Geoffrey,Ventz Steffen,Arfé Andrea,Vanderbeek Alyssa M.,Trippa Lorenzo,Alexander Brian M.

Funder

Burroughs Wellcome Fund (BWF)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Outcomes of Surgical and Transcatheter Aortic Valve Replacement: A Meta-analysis and Parametric Extrapolation of Clinical Trials;Journal of Surgical Research;2024-10

2. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis;Frontiers in Pharmacology;2024-08-22

3. Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3” by M. P. Goetz et al.;Annals of Oncology;2024-08

4. Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach;BMC Cancer;2024-07-22

5. Evaluation of Overall Survival by Restricted Mean Survival Time of Advanced Biliary Tract Cancer treated with Immunotherapy: A Systematic Review and Meta-Analysis;Cancers;2024-05-30